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Since the completion of the Human Genome Project, the hope that genetic markers would enable a 
predictive and preventive medicine, geared towards one’s genetic constitution, has gradually been 
proven vain. The actual results harvested from genetic and genomic research  have  been 
disappointing compared to the promises and expectations  raised.  This  has  not  discouraged 
biomedical researchers and policy makers, however, to keep pursuing the ideal of predictive, 
preventive and, in particular, personalized (PPP--‐) medicine. Their focus of attention has shifted, and 
now ‘biomarkers’ seem to have replaced ‘genes’ as the hope for the future of PPP--‐medicine. 
 
This rise of interest in ‘biomarkers’ indicates a conceptual shift in biomedicine that is philosophically 
interesting for more than one reason. The most commonly used definition of a biomarker is “a 
characteristic that is objectively measured and evaluated as an indicator of normal biological 
processes, pathogenic processes, or pharmacologic responses to a  therapeutic  intervention”  (1). 
Thus, a biomarker is a technologically and scientifically constituted entity, that is interpreted as a sign 
of real time bodily processes. A biomarkers is, then, a translator, opening up the domain of the body 
for discussion (and intervention). This is not a new phenomenon in medicine: cholesterol, blood 
pressure or PSA--‐levels are just some of the biomarkers ‘avant la lettre’ that have been around for 
  
quite some time. What is new, however, is that biomarkers are now sought for mainly on  
the molecular level (RNA, proteins), as well as the sheer increase in number of proposed 
biomarkers (2). 
 
In addition, even though the phenomenon in itself may not be new, both the status of 
biomarkers and their role as a translator are philosophically opaque. First: What exactly is a 
biomarker? How can it be recognized? How does technology constitute this phenomenon 
and how does that determine the way it opens up the body for investigation and 
intervention? And secondly: How do biomarkers distinguish between ‘normal’ and 
‘abnormal’ biological processes? Which concept of normality/abnormality is presupposed? 
And which concept of disease does it reinforce? And, taking the answers to the afore 
mentioned questions into account, how plausible is it that biomarkers will help establish 
PPP--‐medicine and if so, what would it look like? 
 
In this presentation, I will first offer a brief overview of the  way  the  search  for  biomarkers  
now informs biomedical research and research policy. Subsequently, I will go into the 
ontological and epistemological issues raised by the concept ‘biomarker’, using  (among  
others)  the  work  of Canguilhem (3) to reflect on the concept of (ab--‐)normality implied 
in most biomarker research. In conclusion, I will indicate how the philosophical questions 
and doubts  raised  by  biomarkers  may impact the plausibility of the PPP--‐vision of the 
future of medicine. 
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